Table 3.

Sex differences with respect to treatment with GLP-1 RAs. RAs: glucagon-like peptide 1 receptor agonists; CVD: cardiovascular disease; MACE: major adverse cardiovascular events; WC: waist circumference; BP: blood pressure; GI AE: gastrointestinal adverse events; LDL-C: low-density lipoprotein cholesterol.

	Differences in Response
Hypoglycemic efficacy	No sex differences noted in the majority of studies (ref. [21,50,51]) Female superiority noted in a few studies (ref. [5,6,52,53,54]) Male superiority noted in one study (ref. [22])
Weight loss	Female superiority noted in the majority of studies (ref. [6,22,50,56,57])
MACE CVD risk factors i. WC ii. BP iii. Lipid profile	No sex differences noted (ref. [68,69]) Higher risk in females (ref. [66] Lower risk in females (ref. [70]) Similar reduction between sexes (ref. [5]) Similar reduction between sexes (ref. [5,21]) Similar alterations (except for no reduction of LDL-C in females ref. [21])
Adverse events i. GI AE ii. Headaches iii. Hypoglycemia	More frequent in females (ref. [57,73,76]) More frequent in females (ref. [76]) No sex differences noted (ref. [57])